Tellurium (Te) nanostructures are synthesized using green aloe vera chemistry methods, and the synthesized Te tructures provide methods of inhibiting bacterial cells and cancer cells without cytotoxicity towards normal cells. The aloe vera chemistry methods for synthesizing Te nanostructures do not produce toxic byproducts and do not require toxic reagents in comparison to traditional chemical synthetic methods for making Te nanostructures.

Disclosed are lung-targeted extracellular vesicles (EVs) loaded with an anti-inflammatory cargo, as well as compositions, systems, and methods for making same. The disclosed EVs can contain a lung targeted ligand, such as a fusion protein containing a lung targeting moiety. Also disclosed is a composition comprising an EV containing the disclosed fusion protein. In some embodiments, the EV is loaded with an anti-inflammatory cargo. Also disclosed is an EV-producing cell engineered to produce the disclosed EVs. Also disclosed is a method for making the disclosed EVs that involves culturing the disclosed EV-producing cells under conditions suitable to produce EVs.

The present invention explored PLGA NPs synthesis using plant extracts as surfactants by nanoprecipitation process. PLGA NPs synthesized using Camellia sinensis, Dendrocalamus hamiltonii, Ficus palmata and Rubus ellipticus leaf extracts were further explored for encapsulation, controlled and sustained release of well-known antioxidant molecule, curcumin. This plant extract based nanoprecipitation process for the synthesis of PLGA NPs can be further explored for encapsulation of many other antioxidant molecules of therapeutic importance.

The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.

Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.

This invention relates to exosome compositions and methods of using them.

An extracellular vesicle includes an exogenous therapeutic component. The exogenous therapeutic component can include a therapeutic polypeptide, a polynucleotide that encodes a therapeutic polypeptide, a therapeutic nucleic acid, or a therapeutic agent. In some embodiments, the extracellular vesicle includes an exosome or purified exosome product (PEP).

Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.

The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.

An adipocyte-targeting DNA nanodrug, and preparation and uses thereof. The drug is composed of an adipocyte-targeting DNA microstructure and tannic acid (TA) in a weight ratio of 1:25-30. Among them, the small molecular antioxidant TA is loaded into the DNA microstructure. The DNA microstructure incorporated with an adipocyte-targeting aptamer sequence can specifically recognize and bind with adipocytes. TA and DNA microstructure can interact with each other through multiple hydrogen bonds to form the adipocyte-targeting, safe and efficient DNA nanodrug.